# GSK regulatory milestones show why London cannabis > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/gsk-regulatory-milestones-show-why-london-cannabis-attention-remains-selective/ > **Published:** 2026-08-25T12:30:54-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:42:40-04:00 > **Clinical Summary:** Explore how GSK's regulatory milestones highlight the importance of clinical evidence and manufacturing standards in cannabis medicine. --- ✦ New CED Clinical Relevance #67 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. PolicyNeurologyResearchCBDTHCMental HealthSafety Why This Matters This article highlights the importance of clinical evidence and manufacturing standards in the development of cannabis-based medicines. For clinicians and their patients, understanding these regulatory milestones can ensure the use of effective and safe treatments derived from cannabis. The focus on clinical evidence over the source of cannabinoids underscores the need for evidence-based approaches in integrating cannabis into clinical practice. Clinical Summary This article discusses regulatory milestones achieved by GSK in the development of a [cannabis-based medicine](https://cedclinic.com/former-nfl-quarterback-urges-athletes-to-consider-cbd-products/), emphasizing that the quality and efficacy of the product are more important than the source of cannabinoids for clinicians and patients. The practical takeaway is that as more pharmaceutical companies invest in [cannabis research](https://cedclinic.com/pediatric-cannabis-certification-care-children/), clinicians should focus on evidence-based products when considering treatment options for their patients. Dr. Caplan’s Take “As a family physician specializing in [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) for over two decades, I’ve seen the potential of this plant transform lives. However, it’s crucial to emphasize that the efficacy and safety of any cannabis-based treatment hinges on robust clinical evidence from human trials – not just regulatory milestones or manufacturing capabilities. London’s selective attention towards cannabis remains justified until we have more conclusive data.” Clinical Perspective 🔬 In the context of the recent developments in [cannabis regulation](https://cedclinic.com/marijuana-rescheduling-regulatory-updates-march-2026/), it’s worth noting that GSK’s regulatory milestones underscore a crucial point: the focus on cannabis-related products should be guided primarily by robust clinical evidence and stringent manufacturing standards. While the source of cannabinoids may vary, the efficacy, safety, and quality of these products are paramount in clinical practice. As healthcare providers, we must remain vigilant about potential confounders and caveats, ensuring that any recommendations we make are grounded in [evidence-based medicine](https://cedclinic.com/digital-health-expertise-modern-challenge/). Practically speaking, this means staying informed about ongoing research and regulatory updates to provide our patients with the most effective and safe cannabis-derived treatments available. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20GSK%20regulatory%20milestones%20show%20why%20London%20cannabis%20attention%20remains%20selective%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D74810)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D74810)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20GSK%20regulatory%20milestones%20show%20why%20London%20cannabis%20attention%20remains%20selective%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2F%3Fp%3D74810)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) 📰 Source: [https://kalkinemedia.com/uk/stocks/cannabis/gsk-regulatory-milestones-show-why-london-cannabis-attention-remains-selective](https://kalkinemedia.com/uk/stocks/cannabis/gsk-regulatory-milestones-show-why-london-cannabis-attention-remains-selective) Further Reading CED Clinic Blog[Why Cannabis Works](https://cedclinic.com/why-cannabis-works/) Evidence Watch[Cannabis and Heart Health](https://cedclinic.com/cannabis-cardiovascular-health-study/) CED Clinic Blog[Cannabis for Sleep](https://cedclinic.com/cannabis-for-sleep/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).